Nigel S Key

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/6668837/publications.pdf

Version: 2024-02-01

		38720	37183
184	10,140	50	96
papers	citations	h-index	g-index

219	219	219	10018
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Guidelines for the management of hemophilia. Haemophilia, 2013, 19, e1-47.	1.0	1,538
2	Role of the Extrinsic Pathway of Blood Coagulation in Hemostasis and Thrombosis. Arteriosclerosis, Thrombosis, and Vascular Biology, 2007, 27, 1687-1693.	1.1	549
3	Definitions in hemophilia: communication from the SSC of the ISTH. Journal of Thrombosis and Haemostasis, 2014, 12, 1935-1939.	1.9	530
4	Sickle blood contains tissue factorâ€“positive microparticles derived from endothelial cells and monocytes. Blood, 2003, 102, 2678-2683.	0.6	483
5	Home Treatment of Mild to Moderate Bleeding Episodes Using Recombinant Factor VIIa (Novoseven) in Haemophiliacs with Inhibitors. Thrombosis and Haemostasis, 1998, 80, 912-918.	1.8	350
6	Efficacy, safety, and pharmacokinetics of emicizumab prophylaxis given every 4 weeks in people with haemophilia A (HAVEN 4): a multicentre, open-label, non-randomised phase 3 study. Lancet Haematology,the, 2019, 6, e295-e305.	2.2	252
7	Whole Blood Tissue Factor Procoagulant Activity Is Elevated in Patients With Sickle Cell Disease. Blood, 1998, 91, 4216-4223.	0.6	227
8	Sickle cell trait and the risk of venous thromboembolism among blacks. Blood, 2007, 110, 908-912.	0.6	212
9	Coagulation factor concentrates: past, present, and future. Lancet, The, 2007, 370, 439-448.	6.3	184
10	In vitro activation of coagulation by human neutrophil DNA and histone proteins but not neutrophil extracellular traps. Blood, 2017, 129, 1021-1029.	0.6	183
11	Tumor-derived tissue factor activates coagulation and enhances thrombosis in a mouse xenograft model of human pancreatic cancer. Blood, 2012, 119, 5543-5552.	0.6	176
12	Homogeneous low-molecular-weight heparins with reversible anticoagulant activity. Nature Chemical Biology, 2014, 10, 248-250.	3.9	173
13	Association of Sickle Cell Trait With Chronic Kidney Disease and Albuminuria in African Americans. JAMA - Journal of the American Medical Association, 2014, 312, 2115.	3.8	167
14	Hypercoagulability in Sickle Cell Disease: New Approaches to an Old Problem. Hematology American Society of Hematology Education Program, 2007, 2007, 91-96.	0.9	166
15	Coagulation Abnormalities and Thrombosis in Patients Infected With SARS-CoV-2 and Other Pandemic Viruses. Arteriosclerosis, Thrombosis, and Vascular Biology, 2020, 40, 2033-2044.	1.1	144
16	Platelet microparticles are heterogeneous and highly dependent on the activation mechanism: Studies using a new digital flow cytometer. Cytometry Part A: the Journal of the International Society for Analytical Cytology, 2007, 71A, 38-45.	1.1	137
17	Inhibitors in congenital coagulation disorders. British Journal of Haematology, 2004, 127, 379-391.	1.2	129
18	Tissue factorâ€“positive tumor microvesicles activate platelets and enhance thrombosis in mice. Journal of Thrombosis and Haemostasis, 2016, 14, 153-166.	1.9	128

#	Article	IF	Citations
19	Neutrophils and neutrophil extracellular traps enhance venous thrombosis in mice bearing human pancreatic tumors. Haematologica, 2020, 105, 218-225.	1.7	117
20	Prospective study of sickle cell trait and venous thromboembolism incidence. Journal of Thrombosis and Haemostasis, 2015, 13, 2-9.	1.9	113
21	Neutrophils: back in the thrombosis spotlight. Blood, 2019, 133, 2186-2197.	0.6	107
22	Microparticle analysis in disorders of hemostasis and thrombosis. Cytometry Part A: the Journal of the International Society for Analytical Cytology, 2016, 89, 111-122.	1.1	104
23	Standardization of microparticle enumeration across different flow cytometry platforms: results of a multicenter collaborative workshop. Journal of Thrombosis and Haemostasis, 2017, 15, 187-193.	1.9	101
24	Coagulation abnormalities of sickle cell disease: Relationship with clinical outcomes and the effect of disease modifying therapies. Blood Reviews, 2016, 30, 245-256.	2.8	99
25	Differential contribution of FXa and thrombin to vascular inflammation in a mouse model of sickle cell disease. Blood, 2014, 123, 1747-1756.	0.6	98
26	Tissue Factor and Its Measurement in Whole Blood, Plasma, and Microparticles. Seminars in Thrombosis and Hemostasis, 2010, 36, 865-875.	1.5	94
27	Tissue factor promotes activation of coagulation and inflammation in a mouse model of sickle cell disease. Blood, 2012, 120, 636-646.	0.6	94
28	Home treatment of mild to moderate bleeding episodes using recombinant factor VIIa (Novoseven) in haemophiliacs with inhibitors. Thrombosis and Haemostasis, 1998, 80, 912-8.	1.8	92
29	Sickle-Cell Trait: Novel Clinical Significance. Hematology American Society of Hematology Education Program, 2010, 2010, 418-422.	0.9	90
30	Elevated hematocrit enhances platelet accumulation following vascular injury. Blood, 2017, 129, 2537-2546.	0.6	90
31	Etranacogene dezaparvovec (AMT-061 phase 2b): normal/near normal FIX activity and bleed cessation in hemophilia B. Blood Advances, 2019, 3, 3241-3247.	2.5	85
32	Association of Coagulation Activation with Clinical Complications in Sickle Cell Disease. PLoS ONE, 2012, 7, e29786.	1.1	85
33	Synthetic oligosaccharides can replace animal-sourced lowâ€“molecular weight heparins. Science Translational Medicine, 2017, 9, .	5.8	82
34	How I treat patients with inherited bleeding disorders who need anticoagulant therapy. Blood, 2016, 128, 178-184.	0.6	80
35	The relationship between pancreatic cancer and hypercoagulability: a comprehensive review on epidemiological and biological issues. British Journal of Cancer, 2019, 121, 359-371.	2.9	78
36	Epidemiologic and clinical data linking factors XI and XII to thrombosis. Hematology American Society of Hematology Education Program, 2014, 2014, 66-70.	0.9	77

#	Article	IF	Citations
37	Excess of heme induces tissue factor-dependent activation of coagulation in mice. Haematologica, 2015, 100, 308-314.	1.7	77
38	Whole blood tissue factor procoagulant activity is elevated in patients with sickle cell disease. Blood, 1998, 91, 4216-23.	0.6	71
39	High Prevalence of Sickle Cell Trait in African Americans with ESRD. Journal of the American Society of Nephrology: JASN, 2010, 21, 413-417.	3.0	70
40	Measurement of microparticle tissue factor activity in clinical samples: A summary of two tissue factor-dependent FXa generation assays. Thrombosis Research, 2016, 139, 90-97.	0.8	70
41	Global assays of fibrinolysis. International Journal of Laboratory Hematology, 2017, 39, 441-447.	0.7	70
42	Whole Blood Tissue Factor Procoagulant Activity Is Elevated in Patients With Sickle Cell Disease. Blood, 1998, 91, 4216-4223.	0.6	70
43	Hyperhomocyst(e)inemia and Thrombophilia. Archives of Pathology and Laboratory Medicine, 2002, 126, 1367-1375.	1.2	66
44	Using heparin molecules to manage COVIDâ€2019. Research and Practice in Thrombosis and Haemostasis, 2020, 4, 518-523.	1.0	64
45	Pharmacokinetics and safety of OBIâ€1, a recombinant B domainâ€deleted porcine factor VIII, in subjects with haemophilia A. Haemophilia, 2012, 18, 798-804.	1.0	61
46	Red blood cell microvesicles activate the contact system, leading to factor IX activation via 2 independent pathways. Blood, 2020, 135, 755-765.	0.6	61
47	Design of anti-inflammatory heparan sulfate to protect against acetaminophen-induced acute liver failure. Science Translational Medicine, 2020, 12, .	5.8	60
48	Analysis of tissue factor positive microparticles. Thrombosis Research, 2010, 125, S42-S45.	0.8	55
49	How to discuss gene therapy for haemophilia? A patient and physician perspective. Haemophilia, 2019, 25, 545-557.	1.0	54
50	Thrombin generation and cellâ€dependent hypercoagulability in sickle cell disease. Journal of Thrombosis and Haemostasis, 2016, 14, 1941-1952.	1.9	53
51	Hormonal contraception, sickle cell trait, and risk for venous thromboembolism among African American women. American Journal of Obstetrics and Gynecology, 2009, 200, 620.e1-620.e3.	0.7	51
52	Sickle Cell Trait and Incident Ischemic Stroke in the Atherosclerosis Risk in Communities Study. Stroke, 2014, 45, 2863-2867.	1.0	51
53	Red blood cells modulate structure and dynamics of venous clot formation in sickle cell disease. Blood, 2019, 133, 2529-2541.	0.6	51
54	Procoagulant microparticles promote coagulation in a factor XIâ€dependent manner in human endotoxemia. Journal of Thrombosis and Haemostasis, 2016, 14, 1031-1042.	1.9	50

#	Article	IF	Citations
55	Microparticles in sickle cell anaemia: promise and pitfalls. British Journal of Haematology, 2016, 174, 16-29.	1.2	50
56	NHFâ€McMaster Guideline on Care Models for Haemophilia Management. Haemophilia, 2016, 22, 6-16.	1.0	50
57	Negative health implications of sickle cell trait in high income countries: from the football field to the laboratory. British Journal of Haematology, 2015, 170, 5-14.	1.2	46
58	Glioblastoma cell populations with distinct oncogenic programs release podoplanin as procoagulant extracellular vesicles. Blood Advances, 2021, 5, 1682-1694.	2.5	46
59	Contact System Activation and Cancer: New Insights in the Pathophysiology of Cancer-Associated Thrombosis. Thrombosis and Haemostasis, 2018, 118, 251-265.	1.8	44
60	A cross-sectional analysis of cardiovascular disease in the hemophilia population. Blood Advances, 2018, 2, 1325-1333.	2.5	43
61	Fundamentals for a Systematic Approach to Mild and Moderate Inherited Bleeding Disorders: An EHA Consensus Report. HemaSphere, 2019, 3, e286.	1.2	43
62	Re-evaluation of hematocrit as a determinant of thrombotic risk in erythrocytosis. Haematologica, 2019, 104, 653-658.	1.7	40
63	Quantification of citrullinated histones: Development of an improved assay to reliably quantify nucleosomal H3Cit in human plasma. Journal of Thrombosis and Haemostasis, 2020, 18, 2732-2743.	1.9	40
64	Platelets and platelet-derived factor Va confer hemostatic competence in complete factor V deficiency. Blood, 2015, 125, 3647-3650.	0.6	38
65	Red blood cell adhesion to hemeâ€activated endothelial cells reflects clinical phenotype in sickle cell disease. American Journal of Hematology, 2018, 93, 1050-1060.	2.0	36
66	Analysis of anticoagulation strategies for venous thromboembolism during severe thrombocytopenia in patients with hematologic malignancies: a retrospective cohort. Leukemia and Lymphoma, 2017, 58, 2573-2581.	0.6	34
67	Sickle Cell Trait Worsens Oxidative Stress, Abnormal Blood Rheology, and Vascular Dysfunction in Type 2 Diabetes. Diabetes Care, 2015, 38, 2120-2127.	4.3	33
68	Thrombin activation of PAR-1 contributes to microvascular stasis in mouse models of sickle cell disease. Blood, 2020, 135, 1783-1787.	0.6	32
69	Hemolytic anemia in protoporphyria: Possible precipitating role of liver failure and photic stress. American Journal of Hematology, 1992, 39, 202-207.	2.0	28
70	Views on methods for monitoring recombinant factor VIIa in inhibitor patients. Seminars in Hematology, 2004, 41, 51-54.	1.8	28
71	Membrane microparticles in VTE and cancer. Thrombosis Research, 2010, 125, S80-S83.	0.8	28
72	Prospective, multicenter study of postoperative deep-vein thrombosis in patients with haemophilia undergoing major orthopaedic surgery. Thrombosis and Haemostasis, 2016, 116, 42-49.	1.8	28

#	Article	IF	Citations
73	Red blood cell adhesion to ICAM-1 is mediated by fibrinogen and is associated with right-to-left shunts in sickle cell disease. Blood Advances, 2020, 4, 3688-3698.	2.5	28
74	Thrombosis in Cancer: Research Priorities Identified by a National Cancer Institute/National Heart, Lung, and Blood Institute Strategic Working Group. Cancer Research, 2016, 76, 3671-3675.	0.4	27
75	Plasma Microparticle Tissue Factor Activity in Patients With Antiphospholipid Antibodies With and Without Clinical Complications. Thrombosis Research, 2014, 133, 187-189.	0.8	25
76	Prevalence of inherited blood disorders and associations with malaria and anemia in Malawian children. Blood Advances, 2018, 2, 3035-3044.	2.5	25
77	Coagulation activation in sickle cell trait: an exploratory study. British Journal of Haematology, 2015, 171, 638-646.	1.2	24
78	Measuring circulating cell-derived microparticles. Journal of Thrombosis and Haemostasis, 2004, 2, 1848-1850.	1.9	23
79	Impact of an innovative blood factor stewardship program on drug expense and patient care. American Journal of Health-System Pharmacy, 2015, 72, 1579-1584.	0.5	23
80	Recombinant Bâ€domainâ€deleted porcine sequence factor <scp>VIII</scp> (râ€<scp>pFVIII</scp>) for the treatment of bleeding in patients with congenital haemophilia A and inhibitors. Haemophilia, 2017, 23, 33-41.	1.0	23
81	Development and application of global assays of hyperâ€•and hypofibrinolysis. Research and Practice in Thrombosis and Haemostasis, 2020, 4, 46-53.	1.0	23
82	Neutrophil Extracellular Trap Formation and Syndecan-1 Shedding Are Increased After Trauma. Shock, 2021, 56, 433-439.	1.0	23
83	Impact of Sickle Hemoglobinopathies on Pregnancy-Related Venous Thromboembolism. American Journal of Perinatology, 2014, 31, 805-810.	0.6	21
84	Potent irreversible P2Y12 inhibition does not reduce LPS-induced coagulation activation in a randomized, double-blind, placebo-controlled trial. Clinical Science, 2016, 130, 433-440.	1.8	21
85	Microparticles in sickle cell disease. Clinical Hemorheology and Microcirculation, 2018, 68, 319-329.	0.9	21
86	Care models in the management of haemophilia: a systematic review. Haemophilia, 2016, 22, 31-40.	1.0	20
87	Peptides identified on monocyte-derived dendritic cells: a marker for clinical immunogenicity to FVIII products. Blood Advances, 2019, 3, 1429-1440.	2.5	20
88	Assessing a Rare and Serious Adverse Event Following Administration of the Ad26.COV2.S Vaccine. JAMA - Journal of the American Medical Association, 2021, 325, 2445.	3.8	20
89	Prophylactic tranexamic acid in patients with hematologic malignancy: a placebo-controlled, randomized clinical trial. Blood, 2022, 140, 1254-1262.	0.6	20
90	Current Treatment of Venous Thromboembolism. Arteriosclerosis, Thrombosis, and Vascular Biology, 2010, 30, 372-375.	1.1	19

#	Article	IF	Citations
91	Recommended primary outcomes for clinical trials evaluating hemostatic blood products and agents in patients with bleeding: Proceedings of a National Heart Lung and Blood Institute and US Department of Defense Consensus Conference. Journal of Trauma and Acute Care Surgery, 2021, 91, S19-S25.	1.1	19
92	Thrombin-independent contribution of tissue factor to inflammation and cardiac hypertrophy in a mouse model of sickle cell disease. Blood, 2016, 127, 1371-1373.	0.6	17
93	Perioperative management of rare coagulation factor deficiency states in cardiac surgery. British Journal of Anaesthesia, 2017, 119, 354-368.	1.5	17
94	Tissue factor; from Morawitz to microparticles. Transactions of the American Clinical and Climatological Association, 2007, 118, 165-73.	0.9	17
95	Contact and intrinsic coagulation pathways are activated and associated with adverse clinical outcomes in COVID-19. Blood Advances, 2022, 6, 3367-3377.	2.5	17
96	Sickle cell disease and venous thromboembolism in pregnancy and the puerperium. Thrombosis Research, 2015, 135, S46-S48.	0.8	15
97	Recombinant porcine FVIII for bleed treatment in acquired hemophilia A: findings from a single-center, 18-patient cohort. Blood Advances, 2020, 4, 6240-6249.	2.5	15
98	Hemoglobin levels and coronary heart disease risk by age, race, and sex in the reasons for geographic and racial differences in stroke study (REGARDS). American Journal of Hematology, 2020, 95, 258-266.	2.0	14
99	Plasmin-mediated Cleavage of High Molecular Weight Kininogen Contributes to Acetaminophen-Induced Acute Liver Failure. Blood, 2021, 138, 259-272.	0.6	14
100	Hemodialysis-Related Complement and Contact Pathway Activation and Cardiovascular Risk: A Narrative Review. Kidney Medicine, 2021, 3, 607-618.	1.0	14
101	Postoperative bleeding complications in patients with hemophilia undergoing major orthopedic surgery: A prospective multicenter observational study. Journal of Thrombosis and Haemostasis, 2022, 20, 857-865.	1.9	14
102	Lower doses of recombinant porcine factor <scp>VIII</scp> maintain excellent haemostatic efficacy. Haemophilia, 2016, 22, e549-e551.	1.0	13
103	Nephrin as a biomarker of sickle cell glomerulopathy in Malawi. Pediatric Blood and Cancer, 2018, 65, e26993.	0.8	13
104	Excessive breakthrough bleeding in haemophilia B patients on factor IXâ€albumin fusion protein prophylactic therapy: A single centre case series. Haemophilia, 2020, 26, e23-e25.	1.0	13
105	Effects of Tranexamic Acid Prophylaxis on Bleeding Outcomes in Hematologic Malignancy: The a-TREAT Trial. Blood, 2020, 136, 1-2.	0.6	13
106	Platelet Tissue Factor: How Did It Get There and Is It Important?. Seminars in Hematology, 2008, 45, S16-S20.	1.8	12
107	Variant hemoglobin phenotypes may account for differential erythropoiesis-stimulating agent dosing in African-American hemodialysis patients. Kidney International, 2011, 80, 992-999.	2.6	12
108	Establishing sickle cell diagnostics and characterizing a paediatric sickle cell disease cohort in Malawi. British Journal of Haematology, 2016, 174, 325-329.	1.2	12

#	Article	IF	Citations
109	Pregnancy in sickle cell trait: what we do and donâ€™t know. British Journal of Haematology, 2020, 190, 328-335.	1.2	12
110	Protocol Adherence When Managing Massive Bleeding Following Complex Cardiac Surgery: A Study Design Pilot. Journal of Cardiothoracic and Vascular Anesthesia, 2015, 29, 303-310.	0.6	11
111	Variability in Institutional Guidance for COVID-19-Associated Coagulopathy in the United States. Thrombosis and Haemostasis, 2020, 120, 1725-1732.	1.8	11
112	Sickle cell trait is not associated with an increased risk of heart failure or abnormalities of cardiac structure and function. Blood, 2017, 129, 799-801.	0.6	10
113	Biomarkers in cancer patients at risk for venous thromboembolism: data from the AVERT study. Thrombosis Research, 2020, 191, S31-S36.	0.8	10
114	Red blood cells and thrombin generation in sickle cell disease. Thrombosis Research, 2014, 133, S52-S53.	0.8	9
115	Thirtyâ€year risk of ischemic stroke in individuals with sickle cell trait and modification by chronic kidney disease: The atherosclerosis risk in communities (ARIC) study. American Journal of Hematology, 2019, 94, 1306-1313.	2.0	9
116	D-Dimer Enhances Risk-Targeted Thromboprophylaxis in Ambulatory Patients with Cancer. Oncologist, 2020, 25, 1075-1083.	1.9	9
117	Coagulation inhibition for sepsis. Current Opinion in Hematology, 2002, 9, 416-421.	1.2	8
118	Global assays of fibrinolysis. International Journal of Laboratory Hematology, 2017, 39, e142-e143.	0.7	8
119	Protease: Serpin complexes to assess contact system and intrinsic pathway activation. Research and Practice in Thrombosis and Haemostasis, 2020, 4, 789-798.	1.0	8
120	Tissue factor activity is increased in neutrophils from <scp>JAK2 V617F</scp>â€mutated essential thrombocythemia and polycythemia vera patients. American Journal of Hematology, 2022, 97, .	2.0	8
121	Joint <scp>WFH</scp>â€<scp>ISTH</scp> session: issues in clinical trial design. Haemophilia, 2014, 20, 137-144.	1.0	7
122	Genetic basis of ethnic disparities in VTE risk. Blood, 2016, 127, 1844-1845.	0.6	7
123	In vitro and in vivo characterization of a reversible synthetic heparin analog. Thrombosis Research, 2016, 138, 121-129.	0.8	7
124	High molecular weight kininogen contributes to early mortality and kidney dysfunction in a mouse model of sickle cell disease. Journal of Thrombosis and Haemostasis, 2020, 18, 2329-2340.	1.9	7
125	Bench to bedside: new developments in our understanding of the pathophysiology of thrombosis. Journal of Thrombosis and Thrombolysis, 2013, 35, 342-345.	1.0	6
126	Tranexamic acid rapidly inhibits fibrinolysis, yet transiently enhances plasmin generation in vivo. Blood Coagulation and Fibrinolysis, 2021, 32, 172-179.	0.5	6

#	Article	IF	Citations
127	Emicizumab reduces reâ€hospitalization for bleeding in acquired haemophilia A. Haemophilia, 2021, 27, e585-e588.	1.0	6
128	Euglobulin clot lysis time reveals a high frequency of fibrinolytic activation in trauma. Thrombosis Research, 2021, 204, 22-28.	0.8	6
129	Protective and detrimental effects of neuroectodermal cellâ€"derived tissue factor in mouse models of stroke. JCI Insight, 2016, 1, .	2.3	6
130	Advances in Clinical and Basic Science of Coagulation: Illustrated abstracts of the 9th Chapel Hill Symposium on Hemostasis. Research and Practice in Thrombosis and Haemostasis, 2018, 2, 407-428.	1.0	5
131	Association of Sickle Cell Trait With Incidence of Coronary Heart Disease Among African American Individuals. JAMA Network Open, 2021, 4, e2030435.	2.8	5
132	Effect of eptifibatide on inflammation during acute pain episodes in sickle cell disease. American Journal of Hematology, 2018, 93, E99-E101.	2.0	4
133	Initial strides for invent-VTE: Towards global collaboration to accelerate clinical research in venous thromboembolism. Thrombosis Research, 2018, 163, 128-131.	0.8	4
134	Inhibitors and mortality in persons with nonsevere hemophilia A in the United States. Blood Advances, 2020, 4, 4739-4747.	2.5	4
135	Management of inhibitors in persons with nonâ€severe hemophilia <scp>A</scp> in the <scp>United States</scp>. American Journal of Hematology, 2021, 96, E9-E11.	2.0	4
136	Thrombotic Thrombocytopenic Purpura associated with Pembrolizumab. Journal of Oncology Pharmacy Practice, 2022, 28, 979-982.	0.5	4
137	Current insights on the risk of thrombogenicity with off-label use of rFVIIa. Clinical Advances in Hematology and Oncology, 2006, 4, 34-5.	0.3	4
138	Management of adult non-severe haemophilia A patients with inhibitors: a practice-pattern survey. Haemophilia, 2015, 21, e422-e424.	1.0	3
139	Association of sickle cell trait with measures of cognitive function and dementia in African Americans. ENeurologicalSci, 2019, 16, 100201.	0.5	3
140	Quantitative HLAâ€classâ€II/factor VIII (FVIII) peptidomic variation in dendritic cells correlates with the immunogenic potential of therapeutic FVIII proteins in hemophilia A. Journal of Thrombosis and Haemostasis, 2020, 18, 201-216.	1.9	3
141	Outcomes for studies assessing the efficacy of hemostatic therapies in persons with congenital bleeding disorders. Haemophilia, 2021, 27, 211-220.	1.0	3
142	Pharmacokinetics of perioperative FVIII in adult patients with haemophilia A: An external validation and development of an alternative population pharmacokinetic model. Haemophilia, 2021, 27, 974-983.	1.0	3
143	Proteomics in the Study of Qualitative Platelet Defects: Validation of the Approach in the Gray Platelet Syndrome and Quebec Platelet Disorder.. Blood, 2007, 110, 3900-3900.	0.6	3
144	Type-2 Phosphatidylserine (PS)-Positive Erythrocytes and Their Association with Markers of Hemolysis and Hemostatic Activation in Children with Sickle Cell Disease (SCD). Blood, 2015, 126, 943-943.	0.6	3

#	Article	IF	Citations
145	Tissue factor as a therapeutic target. Thrombosis and Haemostasis, 2001, 85, 375-6.	1.8	3
146	<scp>Antithrombinâ€III</scp> mitigates thrombinâ€mediated endothelial cell contraction and sickle red blood cell adhesion in microscale flow. British Journal of Haematology, 2022, 198, 893-902.	1.2	3
147	DDAVP trial in discrepant nonâ€severe haemophilia A patients. Haemophilia, 2018, 24, e152-e154.	1.0	2
148	Upregulation of Tissue Factor May Contribute to Thrombosis in Polycythemia Vera and Essential Thrombocythemia. Blood, 2018, 132, 2513-2513.	0.6	2
149	All-Cause and Inhibitor-Related Mortality in Non-Severe Hemophilia Î' Patients in the United States. Blood, 2019, 134, 902-902.	0.6	2
150	Administration of FFP Repletes and Sustains the Megakaryocyte/Platelet-Derived Factor V Pool To Confer Hemostatic Competence in a Factor V-Deficient Individual.. Blood, 2005, 106, 1779-1779.	0.6	2
151	Treatment of Venous Thromboembolism in Patients with Hematological Malignancies and Severe Thrombocytopenia: A Retrospective Cohort Analysis. Blood, 2016, 128, 531-531.	0.6	2
152	Pathologically stiff erythrocytes impede contraction of blood clots: Comment. Journal of Thrombosis and Haemostasis, 2021, 19, 2893-2894.	1.9	2
153	Alteration of the Structure and Dynamics of Venous Clot Formation in Human and Murine Sickle Cell Disease. Blood, 2016, 128, 2478-2478.	0.6	2
154	Adhesion of Sickle RBCs to Heme-Activated Endothelial Cells Correlates with Patient Clinical Phenotypes. Blood, 2017, 130, 959-959.	0.6	2
155	Histones Induce the Release of Extracellular Hemoglobin and Red Blood Cell-Derived Microvesicles with Procoagulant Activity. Blood, 2018, 132, 2514-2514.	0.6	2
156	Diagnostic approaches to bleeding disorders. Hematology, 2005, 10, 29-32.	0.7	1
157	Vascular haemostasis. Haemophilia, 2010, 16, 146-151.	1.0	1
158	OC-04 - Tissue factor positive microvesicles activate platelets in vitro and in vivo and enhance thrombosis in mice. Thrombosis Research, 2016, 140, S169-S170.	0.8	1
159	Prolonged Remission of Cancer of Unknown Primary following Initiation of Eculizumab Therapy for Paroxysmal Nocturnal Hemoglobinuria. Case Reports in Hematology, 2019, 2019, 1-3.	0.3	1
160	An exploratory study of the effects of strenuous exercise on markers of coagulation activation, circulating microparticles, and inflammation in sickle cell trait. EJHaem, 2020, 1, 251-254.	0.4	1
161	A pilot study of the effect of rivaroxaban in sickle cell anemia. Transfusion, 2021, 61, 1694-1698.	0.8	1
162	Sickle Cell Trait, Oral Contraceptives, and the Risk of Venous Thromboembolism.. Blood, 2007, 110, 1627-1627.	0.6	1

#	Article	IF	Citations
163	Glycosaminoglycans as Anticoagulants in Mucopolysaccharidosis Type I (MPS I).. Blood, 2007, 110, 2160.5-2160.5.	0.6	1
164	Recombinant Porcine Factor VIII Use in Bleed Treatment in Non-Severe Hemophilia a Inhibitor Patients: Dosing Strategies and Efficacy. Blood, 2018, 132, 1202-1202.	0.6	1
165	Enhanced VTE Risk Stratification in Ambulatory Patients with Cancer. Blood, 2019, 134, 634-634.	0.6	1
166	High Molecular Weight Kininogen but Not Factor XII Deficiency Attenuates Acetaminophen-Induced Liver Injury in Mice. Blood, 2019, 134, 3621-3621.	0.6	1
167	Rituximab Monotherapy Is Effective for Inhibitor Eradication with Concomitant Porcine Factor VIII Followed By Emicizumab for Bleed Control in Acquired Hemophilia a. Blood, 2021, 138, 348-348.	0.6	1
168	New players in Trousseau syndrome. Blood, 2015, 126, 1270-1272.	0.6	0
169	Cluster of inhibitors among adult inpatients with haemophilia in a single institution. Haemophilia, 2015, 21, e325-e328.	1.0	0
170	Corrigendum to â€œMeasurement of microparticle tissue factor activity in clinical samples: A summary of two tissue factor-dependent FXa generation assaysâ€•[Thromb. Res. 139 (2016) 90â€“97]. Thrombosis Research, 2016, 147, 63.	0.8	0
171	Harold Ross Roberts, <scp>MD</scp>, 1930â€2017. Haemophilia, 2018, 24, 13-14.	1.0	0
172	Biomarker-enhanced VTE risk stratification in ambulatory patients with cancer. Thrombosis Research, 2020, 196, 437-443.	0.8	0
173	Recombinant porcine factor VIII use in bleed treatment in nonâ€severe haemophilia A inhibitor patients: Dosing strategies and efficacy. Haemophilia, 2021, 27, e147-e150.	1.0	0
174	Phosphatidylserine-Positive Erythrocytes Modulate Tissue Factor Activity In Vivo and In Vitro in Sickle Cell Disease.. Blood, 2004, 104, 240-240.	0.6	0
175	Glycosaminoglycans as Anticoagulants in Mucopolysaccharidosis Type I (MPS I).. Blood, 2007, 110, 3951-3951.	0.6	0
176	Abstract 607: Kininogen Regulates Thrombin Generation in a Mouse Model of Sickle Cell Disease. Arteriosclerosis, Thrombosis, and Vascular Biology, 2015, 35, .	1.1	0
177	HemobloginA2 Levels Associate with Lower ESA-Dose in African-Americans with Sickle Cell Trait and End-Stage Kidney Disease. Blood, 2015, 126, 3407-3407.	0.6	0
178	Purified DNA, but Not Neutrophil Extracellular Traps (NETs), Promotes Contact Activation of Coagulation. Blood, 2015, 126, 767-767.	0.6	0
179	Early Renal Disease in Children with Sickle Cell Disease from Malawi. Blood, 2016, 128, 1316-1316.	0.6	0
180	Emizicumab Promotes Factor Xa Generation on Activated Endothelium in a Blood Cell-Independent Manner. Blood, 2021, 138, 3182-3182.	0.6	0

#	Article	IF	Citations
181	Utility of Inferior Vena Cava Filter in the Management of Venous Thromboembolism Among Patients with Brain Metastases: A Population-Based Study. Blood, 2020, 136, 47-48.	0.6	0
182	Venous Thromboembolism Incidence and Impact on Survival in Patients with Brain Metastases. Blood, 2020, 136, 1-1.	0.6	0
183	Prevalence and outcomes of dehydration in adults with sickle cell trait: the Atherosclerosis Risk in Communities (ARIC) study. British Journal of Haematology, 2022, , .	1.2	0
184	Abstract 594: Characterization of Anti-thrombotic and Anti-inflammatory Properties of New Synthetic, Protamine Reversible Low Molecular Weight Heparin. Arteriosclerosis, Thrombosis, and Vascular Biology, 2015, 35, .	1.1	0